B. Shaddinger

发表

Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function

A. Lindsay, A. Cobitz, S. Caltabiano, 2022, Clinical pharmacology in drug development.

Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.

Z. Fayad, M. Farkouh, Esad Vucic, 2014, Journal of the American College of Cardiology.

Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.

M. Shabbout, G. Vlasakakis, A. Nino, 2019, Diabetes research and clinical practice.

Evaluation of vardenafil and sildenafil on cardiac repolarization.

Timothy H. Montague, G. Dabiri, V. Sethuraman, 2004, The American journal of cardiology.

Effect of Albiglutide on Cholecystokinin‐Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study

J. Billiard, A. Nino, M. Young, 2017, Journal of clinical pharmacology.

Utility of concentration‐effect modeling and simulation in a thorough QT study of losmapimod

L. Tombs, N. Arya, B. Patel, 2015, Journal of clinical pharmacology.

Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials

Yanmei Xu, D. Sprecher, J. Lepore, 2014, PloS one.

An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.

Zixing Fang, B. Shaddinger, M. Magee, 2014, British Journal of Clinical Pharmacology.

The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.

J. Soffer, B. Shaddinger, M. Magee, 2015, British journal of clinical pharmacology.

A definitive study of the effects of PDE‐5 inhibitors on cardiac repolarization in middle‐age males

G. Dabiri, V. Sethuraman, J. Morganroth, 2004 .